-
【CSCO 2022 Preview】CHOICE-01 research promotes precision treatment of lung cancer
Time of Update: 2022-10-31
com/s/BtA15kwZn3_XtHsRxgMQaw Compared with lung adenocarcinoma, patients with lung squamous cell carcinoma have a worse prognosis and are more challenging to treat.
com/s/BtA15kwZn3_XtHsRxgMQaw Compared with lung adenocarcinoma, patients with lung squamous cell carcinoma have a worse prognosis and are more challenging to treat.
-
European Radiology: white matter changes in patients with different prognosis after radiotherapy for nasopharyngeal carcinoma
Time of Update: 2022-10-31
Recently, a study published in the journal European Radiology delineated different patterns of longitudinal WM volume changes in patients with and without RNA in patients with nasopharyngeal carcinoma, and used machine learning methods to construct a predictive model of early WM volume changes after RN and RT.
-
Clin Cancer Res: ctDNA monitoring predicts treatment response and early progression risk for follicular lymphoma
Time of Update: 2022-10-31
EFS rate in ctDNA-positive or negative patients during follow-upctDNA levels before treatment, as haploid genomic equivalents (hGE/mL), were higher in patients who did not achieve a complete response (p=0.
-
JAMA Oncol: Anti-atecilizumab antibodies are associated with poor clinical prognosis in patients with advanced liver cancer
Time of Update: 2022-10-31
Progression-free survival and overall survival in patients with different ADA levels in both cohortsBoth in the discovery and validation cohorts, high ADA levels at C2D1 were associated with reduced response rates with Atezo/Bev treatment compared with patients with low ADA levels (found cohort: 34 versus 11 percent; Validation cohort: 29 versus 7 percent), shorter progression-free lifetime (HR: discovery cohort: 2.
-
European Radiology: The use of radiomics in assessing response to whole-brain radiation therapy
Time of Update: 2022-10-31
Figure ROC curve comparison between training group (A) and validation group (B) to assess WBRT treatment responseThe radiology-clinical machine learning model containing CET1-w (3D) MR sequence features proposed in this study can be used to evaluate the treatment response of WBRT, where the SHAP method used can assist clinicians in guiding personalized WBRT strategies in patients with brain metastases.
-
Nature BE: Breaking through the blood-brain barrier, the new AAV variant helps treat brain tumors and central nervous system genetic diseases
Time of Update: 2022-10-31
On October 10, 2022, Fengfeng Bei's team from the Department of Neurosurgery, Brigham and Women's Hospital, Harvard University, USA, published an online publication in the journal Nature Biomedical Engineering entitled : Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates Research paper.
-
【Probe 24H】New anti-cancer technology may cure advanced cancer! Scientists successfully cultivated hair follicles in vitro
Time of Update: 2022-10-31
BioDiscovery will pay attention to the "medicine" smell with you and explore the value of biotechnology!Introduction: New anti-cancer technology may cure advanced cancer; Scientists successfully cultivate hair follicles in vitro; New Korean technology can synthesize artificial bone in large quantities.
-
Nature Cancer: Lui Zhimin/Hatchie team reveals new mechanism to overcome immune checkpoint inhibitor resistance
Time of Update: 2022-10-31
Patients with EGFR mutation-activated non-small cell lung cancer (NSCLC) are not sensitive to immune checkpoint inhibitor therapy, which is the bottleneck of lung cancer immunotherapy. The continuous
-
Current status of drug development targeting KRAS G12C
Time of Update: 2022-10-31
In a recent ESMO, Amgen disclosed the latest results of the CodeBreaK 200 Phase III trial, which brought some benefits to the KRAS G12C inhibitor sotorasib for the treatment of advanced and metastatic non-small cell lung cancer (NSCLC) compared to standard chemotherapy.
-
【CSCO 2022 Preview】Focusing on patients with RAIR-DTC, Professor Lin Yansong of Peking Union will report the phase III results of donafenib
Time of Update: 2022-10-31
com/s/7mJfuwA72xY1YRaSfR5sSg In recent years, the incidence of thyroid cancer has continued to rise, differentiated thyroid cancer (DTC) is the most common type of thyroid cancer, DTC patients after standardized surgical treatment, selective iodine-131 treatment and thyroid-stimulating hormone (TSH) inhibition first-line standard treatment has a good prognosis.
-
European Radiology: Relationship between imaging features of adipose tissue and postoperative complications and overall survival of gastric cancer
Time of Update: 2022-10-31
Recently, a study published in the journal European Radiology evaluated the area and HU of preoperative visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) in gastric cancer patients undergoing radical gastrectomy, and explored the relationship between these indicators and postoperative complications and overall survival (OS) in patients.
-
European Radiology: Are you still having a headache differentiating adrenal pheochromocytoma from lipodeficiency adenoma?
Time of Update: 2022-10-31
Axial T2-weighted (T2W) HASTE image, adenoma (arrow) rated by three radiologists as a homogeneous mass, low intensity (not shown) relative to the renal cortex parenchymaThis study suggests that pheochromocytoma assessed by subjective and quantitative assessment has higher T2-weighted signal intensity and heterogeneity compared with fat-depleted adrenal tumors.
-
JAMA Oncol: Comparison of the advantages and disadvantages of whole brain radiotherapy or stereotactic radiotherapy for brain metastases
Time of Update: 2022-10-31
The study aimed to clarify the association between postoperative whole-brain radiotherapy (WBRT) or stereotactic radiotherapy (SRS) and quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors of 1-4 brain metastases.
-
Inventory: JAK inhibitors
Time of Update: 2022-10-31
●Bristol-Myers Squibb's TYK2 inhibitor Deucravacitinib (trade name Sotyktu) was approved in the United States for the treatment of psoriasis in September 2022, and the current clinical trial indications include psoriatic arthritis, Crohn's disease and systemic lupus erythematosus.
-
【CSCO 2022 Prospect】The domestic drug serplulimab brings new hope to esophageal cancer patients
Time of Update: 2022-10-31
ASTRUM-007 is a randomized, double-blind, multicenter, phase III clinical study with Professor Huang Jing of the Cancer Hospital of the Chinese Academy of Medical Sciences as the principal investigator to compare the efficacy and safety of serplulimab or placebo in combination with chemotherapy in patients with locally advanced/metastatic esophageal squamous cell carcinoma.
-
Exscientia presented novel patient stratification and biomarker data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
Time of Update: 2022-10-31
In this study, researchers leveraged Exscientia's translational oncology platform, combined with AI-based primary cancer tissue analysis and transcriptomics, to understand how cells in different patient populations respond to '617 treatment.
-
Professors Li Jianyong, Qiu Lugui and Ji Chunyan jointly explored the refined whole-process management of CLL patients, allowing patients to bloom the "light of life"
Time of Update: 2022-10-26
Chronic lymphoblastic leukemia (CLL) is a subtype of B-cell lymphoma, mainly occurring in middle-aged and elderly people, clinical progress is relatively slow, and heterogeneous, the incidence of CLL
-
2022 SHS| Professor Huang Haiwen: Strive for the best of good, explore the optimization strategy of autologous hematopoietic stem cell transplantation, analyze the characteristic clinical diagnosis and treatment model, and strive to improve the survival and quality of life of lymphoma patients
Time of Update: 2022-10-26
On this occasion, Yimaitong specially invited Professor Huang Haiwen from the First Affiliated Hospital of Soochow University to interpret the application status and future prospects of autologous hematopoietic stem cell transplantation in lymphoma based on clinical experience, so as to feed readers!
-
Pierce the heart! The taller you are, the greater your risk of cancer! 14% increase for every 10cm height
Time of Update: 2022-10-26
This article is the original of Translational Medicine Network, please indicate the source of reprinting By JevinIt is widely recognized that tall people tend to achieve a state of health after gettin
-
2022 SHS Professor Tang Xiaowen: AML transplantation needs to pay attention to the whole process management, and myeloid CAR-T treatment has broad prospects
Time of Update: 2022-10-26
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, with an increasing incidence with age and a poor overall prognosis. With the deepening of research, the treatment of AML has
